Immuron Ltd (IMRN) company profile
Close on Nov 17, 2026Market cap $7.03MP/E –Yield –
About Immuron
Pharmaceutical Preparations, SIC 2834
Immuron Limited is an Australian biopharmaceutical company engaged in developing and commercializing orally delivered polyclonal antibody therapies targeting mucosal surfaces in the gastrointestinal tract. The company focuses on addressing conditions such as travelers' diarrhea, irritable bowel syndrome, and enteric infections caused by pathogens like Enterotoxigenic Escherichia coli and Clostridioides difficile. Its commercial offerings include Travelan, an over-the-counter formulation designed to lower the incidence of travelers' diarrhea, and ProIBS, an orally administered product containing AVH200 that creates a protective hydrogel barrier to soothe irritable bowel syndrome symptoms. Operating across hyper-immune products and research and development divisions, the business primarily supplies retail consumers and travel health markets through retail pharmacies, clinical practitioners, and online channels.
Headquartered in Carlton South, Victoria, Australia, Immuron markets its commercial products across several international jurisdictions. The enterprise distributes Travelan through pharmacies throughout Australia, sells the product as a licensed natural health item in Canada, and distributes it as a dietary supplement within the United States. ProIBS is marketed to patients and consumers in Australia.
Summary of the business section of Immuron's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Immuron Ltd
- Founded
- 1994
- Headquarters
- Carlton, Victoria, C3
- Address
- 62 Lygon Street, Level 3 3053
- Phone
- 61 03 9824 5254
- Website
- www.immuron.com.au
- Employees
- 7, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- C3
- Fiscal year ends
- June 30
- Auditor
- GRANT THORNTON AUDIT PTY LTD, Melbourne, Victoria
Stock & identifiers
- Ticker
- IMRN
- Exchange
- Nasdaq
- IPO date
- Jun 12, 2017
- Shares outstanding
- 323M, Jun 30, 2026
- Filer category
- Non-accelerated filer
- SEC CIK
- 1660046
- CUSIP
- 45254U101
- ISIN
- US45254U1016
- FIGI
- BBG000LZD9X8
- Share class FIGI
- BBG001T0C840
- LEI
- 529900ZIDI5C9C9TTI91
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul Gerard Brennan | Chairman of the Board, Director | – |
| Flavio Palumbo | Chief Commercial Officer | 1,142,909 |
| Steven George Lydeamore | Chief Executive Officer | 3,155,047 |
| Aaron James Laurita | Chief Financial Officer | – |
| Jerry Kanellos | Chief Scientific Officer | 333,000 |
| Daniel Jude Pollock | Director | 743,230 |
| Jeannette Anne Joughin | Director | – |
| Ravi Savarirayan | Director | 877,840 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 12, 2017
- Offer price
- $9.99
- Securities offered
- 610,000
- Gross proceeds
- $6.09M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Dec 9, 2017
“Per ADS Per Warrant Total Public offering price $ 9.99 $ 0.01 $ 10.00 Underwriting discounts and commissions (1) $ 0.6993 $ 0.0007 $ 0.70 Proceeds, before expenses, to us $ 9.207 $ 0.0093 $ 9.30 (1) Does not include a non-accountable expense allowance equal to 1% of the gross proceeds of this offering payable to Joseph Gunna”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had seven full-time employees and one part time employee.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 10, 2022 | Delisting | Notice of delisting from exchange (Form 25) |
| Oct 31, 2017 | Late filing | Notification of late filing |
| Jun 12, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| May 25, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?